Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives
2016 San Antonio Breast Cancer SymposiumMatthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).
Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).